NuCana plc Files 6-K for Q2 2024 Financials
Ticker: NCNA · Form: 6-K · Filed: Aug 15, 2024 · CIK: 1709626
| Field | Detail |
|---|---|
| Company | Nucana PLC (NCNA) |
| Form Type | 6-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, sec-filing, quarterly-report
Related Tickers: NCNA
TL;DR
NuCana's Q2 2024 financials are in, check the 6-K for performance vs. last year.
AI Summary
NuCana plc filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the second quarter of 2024, comparing it to the same period in 2023. It also provides year-to-date figures for both 2024 and 2023, detailing various financial statement items.
Why It Matters
This filing provides investors with an update on NuCana's financial performance for the second quarter of 2024, allowing for analysis of trends and comparison against prior periods.
Risk Assessment
Risk Level: low — This filing is a routine financial disclosure and does not contain significant new risk factors.
Key Players & Entities
- NuCana plc (company) — Filer of the 6-K report
- 20240630 (date) — End of the reporting period
- 20240815 (date) — Filing date of the report
FAQ
What is the reporting period for this 6-K filing?
The conformed period of report is 20240630, indicating the second quarter of 2024.
When was this 6-K filing submitted to the SEC?
The filing was submitted on 20240815.
What is NuCana plc's Standard Industrial Classification code?
NuCana plc's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What was NuCana plc's former company name?
NuCana plc's former company name was NuCana BioMed Ltd, with a date of name change on 20170619.
What are some of the financial statement items reported for the period ending June 30, 2024?
The filing references items such as Retained Earnings, Reserve of Exchange Differences on Translation, Reserve of Change in Value of Time Value of Options, and Issued Capital for periods including 2023 and 2024.
Filing Stats: 574 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-08-15 16:09:05
Filing Documents
- d625590d6k.htm (6-K) — 79KB
- d625590dex991.htm (EX-99.1) — 488KB
- d625590dex992.htm (EX-99.2) — 90KB
- d625590dex993.htm (EX-99.3) — 87KB
- 0001193125-24-201317.txt ( ) — 2961KB
- ncna-20240630.xsd (EX-101.SCH) — 28KB
- ncna-20240630_cal.xml (EX-101.CAL) — 34KB
- ncna-20240630_def.xml (EX-101.DEF) — 69KB
- ncna-20240630_lab.xml (EX-101.LAB) — 190KB
- ncna-20240630_pre.xml (EX-101.PRE) — 152KB
- d625590d6k_htm.xml (XML) — 485KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. NuCana plc By: /s/ Donald Munoz Name: Donald Munoz Title: Chief Financial Officer Date: August 15, 2024